Targeting the Eph-ephrin system with protein-protein interaction (PPI) inhibitors

Current Drug Targets

Volumn 16, Issue 10, 2015, Pages 1048-1056

  Tognolini, Massimiliano ^a   Lodola, Alessio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Antagonist; Drug discovery; Eph; Ephrin; Protein protein; Small molecules

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2, 6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY] PHENYL] VINYL] BENZOIC ACID; 4[4 CYCLOPENTYLNAPHTHALEN 1 YL] 4 OXOBUTANOIC ACID; BENZOIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CHOLANIC ACID DERIVATIVE; DOXAZOSIN; EPHRIN; EPHRIN A1; EPHRIN RECEPTOR; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A4; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FARNESOID X RECEPTOR; GLYCINE; GLYCOLITHOCHOLIC ACID; LITHOCHOLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL PRODUCT; POLYPHENOL DERIVATIVE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN PROTEIN INTERACTION INHIBITOR; PROTOCATECHUIC ACID; PYROGALLOL; THEAFLAVIN; UNCLASSIFIED DRUG; [3 ALPHA 5 BETA] 3 HYDROXYCHOLAN 24 OIC ACID DERIVATIVE; CHOLIC ACID DERIVATIVE; MOLECULAR LIBRARY; PLANT MEDICINAL PRODUCT; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; IC50; MOLECULAR DOCKING; NONHUMAN; PROTEIN BINDING; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; PROTEIN ANALYSIS;

ANIMALS; BENZOATES; CHOLIC ACIDS; DOXAZOSIN; DRUG DISCOVERY; EPHRINS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLANT PREPARATIONS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTEIN KINASE INHIBITORS; RECEPTORS, EPH FAMILY; SMALL MOLECULE LIBRARIES;

EID: 84945957901     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150825144457     Document Type: Article

References (51)

1. Himanen J-P, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007; 19: 534-42.
2. Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 2003; 17: 1429-50.
3. Kinch MS, Moore M-B, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res Off J Am Assoc Cancer Res 2003; 9: 613-8.
4. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer J Int Cancer 2003; 103: 657- 63.
5. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11: 226-31.
6. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 2011; 15: 31-51.
7. Brantley DM, Cheng N, Thompson EJ, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-26.
8. Dobrzanski P, Hunter K, Jones-Bolin S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004; 64: 910-9.
9. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005; 5: 149-57.
10. Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis 2010; 13: 259-67.
11. Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol 2015; 55: 465-87.
12. Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 2014; 13: 39-62.
13. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52.
14. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80.
15. Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. Therapeutic perspectives of Eph-ephrin system modulation. Drug Discov Today 2013.
16. Stumpf MPH, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA 2008; 105: 6959-64.
17. Jin L, Wang W, Fang G. Targeting protein-protein interaction by small molecules. Ann Rev Pharmacol 2014; 54: 435-56.
18. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014; 14: 248-62.
19. Sperandio O, Reynès CH, Camproux A-C, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 2010; 15: 220-9.
20. Himanen JP. Ectodomain structures of Eph receptors. Semin Cell Dev Biol 2012; 23: 35-42.
21. Himanen JP, Goldgur Y, Miao H, et al. Ligand recognition by Aclass Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep 2009; 10: 722-8.
22. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
23. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-22.
24. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000; 7: 731-48.
25. Toth J, Cutforth T, Gelinas AD, Bethoney KA, Bard J, Harrison CJ. Crystal structure of an ephrin ectodomain. Dev Cell 2001; 1: 83-92.
26. Mohamed IH, Giorgio C, Bruni R, et al. Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. Pharmacol Res Off J Ital Pharmacol Soc 2011; 64: 464-70.
27. Guss JM, Merritt EA, Phizackerley RP, Freeman HC. The structure of a phytocyanin, the basic blue protein from cucumber, refined at 1.8 A resolution. J Mol Biol 1996; 262: 686-705.
28. Noberini R, Koolpe M, Lamberto I, Pasquale EB. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol Res Off J Ital Pharmacol Soc 2012; 66: 363-73.
29. Tang F-Y, Chiang E-PI, Shih C-J. Green tea catechin inhibits ephrin- A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem 2007; 18: 391-9.
30. Roowi S, Stalmach A, Mullen W, Lean MEJ, Edwards CA, Crozier A. Green tea flavan-3-ols: colonic degradation and urinary excretion of catabolites by humans. J Agric Food Chem 2010; 58: 1296- 304.
31. Del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 2013; 18: 1818- 92.
32. Tognolini M, Giorgio C, Mohamed IH, et al. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites. J Agric Food Chem 2012; 60: 8877-84.
33. Pellati F, Bruni R, Righi D, et al. Metabolite profiling of polyphenols in a Terminalia chebula Retzius ayurvedic decoction and evaluation of its chemopreventive activity. J Ethnopharmacol 2013; 147: 277-85.
34. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010; 53: 2719-40.
35. Kosinski C, Li VSW, Chan ASY, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007; 104: 15418-23.
36. Giorgio C, Hassan Mohamed I, Flammini L, et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PloS One 2011; 6: e18128.
37. Zhu W, Groh M, Haupenthal J, Hartmann RW. A detective story in drug discovery: Elucidation of a screening artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase. Chem - Eur J 2013; 19: 8397-400.
38. Fu AKY, Hung K-W, Huang H, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 2014; 111: 9959-64.
39. Tognolini M, Incerti M, Lodola A. Are we using the right pharmacological tools to target EphA4? ACS Chem Neurosci 2014; 5: 1146-7.
40. Noberini R, Koolpe M, Peddibhotla S, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008; 283: 29461-72.
41. Noberini R, De SK, Zhang Z, et al. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des 2011; 78: 667-78.
42. Lodola A, Incerti M, Tognolini M. On the use of 2,5-dimethylpyrrol- 1-yl-benzoic acid derivatives as EPH-ephrin antagonists. J Virol 2014; 88: 12173-12173.
43. Tognolini M, Incerti M, Hassan-Mohamed I, et al. Structureactivity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. Chem Med Chem 2012; 7: 1071-83.
44. Incerti M, Tognolini M, Russo S, et al. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem 2013; 56: 2936-47.
45. Hassan-Mohamed I, Giorgio C, Incerti M, et al. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 2014; 171: 5195-208.
46. Tognolini M, Incerti M, Pala D, et al. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. Chem Med Chem 2014; 3: 67-72.
47. Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000; 43: 2971-4.
48. Gioiello A, Cerra B, Zhang W, et al. Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β- hydroxy-Δ(5)-C27-steroid oxidoreductase deficiency. J Steroid Biochem Mol Biol 2014; 144 Pt B: 348-60.
49. Pala D, Castelli R, Incerti M, et al. Combining ligand- and structure- based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. J Chem Inf Model 2014; 54: 2621- 6.
50. Petty A, Myshkin E, Qin H, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PloS One 2012; 7: e42120.
51. Duggineni S, Mitra S, Noberini R, et al. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol 2013; 85: 507-13.